US GLP-1 Weight-Loss Use Surges to New High Amid Obesity Decline
Gallup’s 2026 Health & Well-Being Index shows 11% of U.S. adults currently use GLP-1 weight-loss drugs (up from 3% in 2024) and 15% have used them ever. Brand-name meds account for 68% of current use, with compounded versions rising to 19% as cost/insurance influence switching. Awareness of GLP-1s is 91%. The obesity rate has declined to 36.4% in 2026, while diabetes rates remain steady, suggesting GLP-1 uptake may be linked to obesity declines. About one-third of compounded users switched from brand-name, mainly for cost reasons. Data come from 5,065 adults surveyed May 28–June 5, 2026.
